Page 779«..1020..778779780781..790800..»

The Benefits of Strength Training: Why Cardio Isn’t Enough – LIVESTRONG.COM

Posted: January 25, 2021 at 5:43 am

You know strength training is key to building muscle, but how bad is it to skip?

Image Credit: LIVESTRONG.com Creative

Official guidelines recommend doing muscle-strengthening activities at least two times per week. But only about a quarter of adults meet those requirements.

That's nearly half as many people who have a regular cardio workout, according to the Centers for Disease Control and Prevention.

"Some people don't know how to resistance train and are worried they might get injured, while others have an injury or condition that doesn't allow them to weight train to a full capacity," says Araceli De Leon, CPT, a certified personal trainer, kinesiologist and spokesperson for the American Council on Exercise.

"In addition, there is a misconception around weight training among some females, who think they might get too bulky or gain too much muscle," she says.

Another common barrier is "gym-timidation," a lack of knowledge about how to use weight-lifting equipment and the intimidation that can come with it. Women, in particular, reported lower comfort using gym facilities, including strength machines and free weights, according to a November 2020 study from Penn State University.

But hey, as long as you're exercising regularly, does skipping out on pumping iron actually matter that much? Is strength training mandatory?

Cardio bunnies, consider this your wake-up call.

Why Doing Cardio Alone Isn't Enough

Let's be clear: We're not knocking a heart-pumping aerobic workout, which is amazing for your health in so many ways. But if you don't also incorporate resistance work, your body will pay the price.

"Your muscles might atrophy you will lose muscle mass and endurance because you're not using your muscles as much," De Leon says. "Your ligaments and tendons can also weaken."

Skipping out on strengthening is also bad for your bones. "Weight training puts stress on your bones, which nudges bone-forming cells into action," De Leon says. "If you don't do resistance exercises, your bones may get weaker and lose some mineral content."

This is especially important for older adults primarily those who are postmenopausal, as the decline in estrogen levels leads to bone loss, increasing your risk of fractures.

In fact, resistance exercise alone or in combination with other forms of physical activity is the ideal training for improving bone mass in postmenopausal women, middle-aged men and older adults, according to a December 2018 review in Endocrinology and Metabolism.

Finally, if weight loss is your goal, you won't torch nearly as many calories without resistance training, says A. Brion Gardner, MD, an orthopedic surgeon specializing in sports medicine at the Centers for Advanced Orthopaedics in Manassas, Virginia.

"When you do a 30-minute cardio session, you are burning calories for that 30 minutes," he says. "But a 30-minute weight-lifting session will have you burning calories for the rest of the day, an effect known as excess post-exercise oxygen consumption."

That's because strength training, by causing microscopic stress to your muscles, triggers your body to enter a recovery state. That muscle recovery uses calories for energy.

Plus, the more lean muscle you have, the more you'll increase your basal metabolic rate, the number of calories you burn each day just to maintain normal biological function. Muscle is metabolically active, meaning it burns more calories at rest than body fat, he says.

The Benefits of Strength Training

Not convinced yet? "There are so many benefits to resistance training, even if you already have an aerobic program," De Leon says. "Because everything in the body is connected, having a solid muscular foundation is important in the way one's body moves, heals and interacts with other body systems."

Just check out all these major payoffs.

You'll Prevent Injury and Promote Healing

Increasing your strength training volume and intensity are associated with a reduced risk in sports injury risks, according to an August 2018 meta-analysis in the British Journal of Sports Medicine.

A 2017 report from the American College of Sports Medicine also shows that following a resistance-training program is associated with a lower incidence of stress fractures, falls and low-back injuries in people who are physically active.

And if you do get hurt? You'll bounce back more quickly and efficiently if you've been sculpting muscles.

"Resistance training strengthens your tendons and ligaments, which can help you recover from injuries, like a sprained ankle or dislocated shoulder," De Leon says. "It will also improve your balance and posture by strengthening the small stabilizers that keep you erect."

It Will Enhance Your Athletic Performance

Runners with a strength-training practice significantly improve their speed and endurance, according to a September 2019 study in the British Journal of Medicine. "Increased muscle fiber size and contractile strength lead to greater physical capacity," De Leon says.

She explains that her own resistance workouts have helped her become stronger in other pursuits. "I'm a long-distance runner, and targeting my leg, core and glute muscles helps me have longer, more successful runs," she says.

Her strength-training routine also allows her to be a more powerful rock climber, stabilizes her in yoga practice and prepares her for snowboarding days.

You May Reduce Your Risk of Disease

A November 2017 study in the Journal of the American Heart Association found that moderate strength training (between 100 to 145 minutes per week) is associated with a lower all-cause mortality risk in older women.

In fact, older adults age 65 and over who followed recommended guidelines to strength train at least twice per week had 46 percent lower odds of all-cause mortality than those who didn't, in a February 2016 study in Preventative Medicine.

But that's not all research shows that women who focus on strengthening their muscles reduce their risk of type 2 diabetes by 30 percent and cardiovascular disease by 17 percent compared with those who don't strength train, according to a January 2017 study in Medicine & Science in Sports & Exercise.

The bottom line: Combining strength training with aerobic exercise is linked to an even lower risk of type 2 diabetes, cardiovascular disease and early death than doing cardio alone.

It Can Help Boost Your Mood

According to a June 2018 meta-analysis in JAMA Psychiatry, resistance training reduces symptoms of mild to moderate depression.

"Resistance training regulates your blood flow and heart rate, which clears away brain fog and pumps you full of feel-good endorphins," De Leon says.

As you perform new feats of strength, your mental strength and confidence will also improve.

You'll Reduce Low-Back Pain

A small May 2020 study in BMC Sports Science, Medicine and Rehabilitation found that people with lower back pain experienced significantly less discomfort and saw improvements in pain-related disability when they followed a strength-training program. (A randomized clinical trial looking at this effect is currently underway.)

De Leon explains that strengthening your core via resistance work lends support to your lumbar spine (lower back), relieving pressure and pain. Bonus: The study participants also reported an increase in energy levels.

You Might Sleep Better at Night

Building muscle may even improve shuteye, according to a small May 2015 study in the Journal of Strength and Conditioning Research, in which people fell asleep faster and had fewer nighttime awakenings on days when they engaged in resistance training.

Which Kind of Strength Training Is Best?

There are many different ways to strength train, but the best modality for you depends on your abilities, goals and needs. Here's the 101.

"Although both machines and free weights, such as dumbbells and kettlebells, allow you to gain a similar amount of muscle size and strength, free weights require more core engagement and activate more muscle groups than a machine," De Leon says. Without the support of a machine to hold you in the proper position, your body is forced to work harder to maintain your posture.

"As a result, free weights are better for building muscle long term, compared to a machine that may only be targeting specific muscles," De Leon says.

Because machines provide more support, they can be a good bet for beginners who haven't yet honed their form. "A machine is also great to work on improving your form and range of motion after an injury," De Leon says.

"These [resistance bands] are cheap and portable," De Leon says. "Although they do increase muscle size and strength, in the long run, they will become less challenging." To make your strength workouts more challenging with resistance bands, you can add them to your dumbbells or kettlebells.

"Body-weight workouts use your own weight to provide resistance against gravity," De Leon says. The best part is that body-weight exercises don't require any special equipment, like weight machines, dumbbells or even resistance bands. You can do them anytime, anywhere, which is especially helpful if you're avoiding the gym during the COVID-19 pandemic.

"To build muscle using body-weight training, gradually increase the amount of reps or train until failure for example, by doing squats until you physically can't do any more," De Leon says. "You can also try a 'time under tension' workout, where you perform each movement very slowly so that it becomes more difficult."

So, How Bad Is It Really to Never Strength Train?

As long as you are still getting an aerobic workout, you're not doomed if you skip pumping iron. "There is no harm per se in not weight training," Dr. Gardner says.

But it's certainly not ideal. "Over time, it can lead to adverse health effects and the loss of fitness gains," De Leon says. "People with a strength-training practice have an overall greater quality of life."

Aim to strength train at least twice per week, and experiment with different types of resistance-training equipment to help you figure out what will help you reach your goals. Because the more you enjoy that activity, the higher the chances you'll stick to a routine.

Ultimately, you'll be better off if you quit resisting resistance training. Now drop and give us 20!

More:
The Benefits of Strength Training: Why Cardio Isn't Enough - LIVESTRONG.COM

Posted in Preventative Medicine | Comments Off on The Benefits of Strength Training: Why Cardio Isn’t Enough – LIVESTRONG.COM

Preventative Healthcare Technologies and Services Market Size, Industry Trends, Leading Players, Share and Forecast 2021-2027 || Myriad Genetics,…

Posted: January 25, 2021 at 5:43 am

Global Preventative Healthcare Technologies and Services Market report provides a basic overview of the industry including growth rate, demand, size, share and forecast. This market research is a combined result of inputs from industry experts with awareness, the experience of industry and qualitative and quantitative synthesis of the market. Additionally, the report enables a market player not only to plan but also execute lucrative Preventative Healthcare Technologies and Services strategies based on growing market needs by emphasizing leading competitors strategic moves which include recent mergers, ventures, acquisitions, busine Preventative Healthcare Technologies and Services expansion, product launches, branding, and promotional activities.

Furthermore, the report Provides Preventative Healthcare Technologies and Services market key strategic developments of the market comprising new product launch, research & development, partnerships, acquisitions & mergers, collaborations & joint ventures agreements, and regional growth of main players in the market on the global and regional basis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-preventative-healthcare-technologies-and-services-market&AS

Global Preventative Healthcare Technologies and Services market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the TOP PLAYERS including:

Detailed Market Analysis and Insights:

Preventative healthcare technologies and services market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to growing at a CAGR of 11.10% in the above-mentioned forecast period. The growing awareness amongst the physicians and patients regarding the benefits of advance technology as well as services will help in boosting the growth of the market.

Preventative Healthcare Technologies and Services Market Segment Analysis:

By Type (Early Detection and Screening Technologies, Chronic Disease Management Technologies, Vaccines, Advanced Technologies to Reduce Errors)

By Application (Hospitals, Clinics, Others)

The cost analysis of the Global Preventative Healthcare Technologies and Services Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. The research carried out after the launch of a new product can help to find loopholes and devise plans to counter that loss and increase the profits. With the reliable Preventative Healthcare Technologies and Services market research report, the chances of loss can be reduced to a large extent.

The research study evaluates the overall size of the market, by making use of a bottom-up approach, wherein data for different industry verticals, and end-user industries and its applications across various product types have been recorded and predicted during the forecast period. The report helps to recognize new areas for expansion, and increase customer base. After discovering potential customers and their needs via the winning Preventative Healthcare Technologies and Servicesreport the same can be incorporated into the clients services.

Read complete report along with TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-preventative-healthcare-technologies-and-services-market&AS

Table of Contents

Global Preventative Healthcare Technologies and Services Market Outlook-by Major Company, Regions, Type, Application and Segment Forecast, 2021 -2027

Chapter 1: Preventative Healthcare Technologies and Services Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: Preventative Healthcare Technologies and Services Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production PricePreventative Healthcare Technologies and Services Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Preventative Healthcare Technologies and Services.

Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Preventative Healthcare Technologies and Services.

Chapter 5: Production Volume, Price, Margin, and Revenue ($) of Preventative Healthcare Technologies and Services by Regions

Chapter 6: Preventative Healthcare Technologies and Services Production, Consumption, Export and Import by Regions.

Chapter 7: Preventative Healthcare Technologies and Services Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Preventative Healthcare Technologies and Services.

Chapter 9: Preventative Healthcare Technologies and Services Market Analysis and Forecast by Type and Application.

Chapter 10: Market Analysis and Forecast by Forecast (2021-2027).

Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12: Market Conclusion of the Whole Report.

Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

Competitive Landscape and Preventative Healthcare Technologies and Services Market Share Analysis:

Preventative healthcare technologies and services market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to preventative healthcare technologies and services market.

The major players covered in the preventative healthcare technologies and services market report are Myriad Genetics, Inc., Quest Diagnostics Incorporated., Medtronic, Abbott., Merck & Co., Inc., GlaxoSmithKline plc., Omnicell, Inc., McKesson Corporation, Pfizer Inc., Dilon Technologies, Inc., OMRON Healthcare Europe B.V., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Global Preventative Healthcare Technologies and Services Market Scope and Market Size:

Preventative healthcare technologies and services market is segmented on the basis of type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on type, preventative healthcare technologies and services market is segmented into early detection and screening technologies, chronic disease management technologies, vaccines, and advanced technologies to reduce errors. Early detection and screening technologies have been further segmented into automated screening, personalized medicine, and other advanced screening technologies. Chronic disease management technologies have been further segmented into blood pressure monitors, asthma monitors, cardiovascular monitors, and glucose monitors.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert@ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-preventative-healthcare-technologies-and-services-market&AS

By Geographical Regions:-

Asia Pacific: China, Japan, India, and Rest of Asia Pacific

Europe: Germany, the UK, France, and Rest of Europe

North America: The US, Mexico, and Canada

Latin America: Brazil and Rest of Latin America

Middle East & Africa: GCC Countries and Rest of Middle East & Africa

If you have any special requirements, please let us know and we will offer you the report as you want.

This Report Answers the Following Questions:

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:-corporatesales@databridgemarketresearch.com

Read more:
Preventative Healthcare Technologies and Services Market Size, Industry Trends, Leading Players, Share and Forecast 2021-2027 || Myriad Genetics,...

Posted in Preventative Medicine | Comments Off on Preventative Healthcare Technologies and Services Market Size, Industry Trends, Leading Players, Share and Forecast 2021-2027 || Myriad Genetics,…

Regenerative medicine is advancing health care in diverse ways – Hometown Focus

Posted: January 23, 2021 at 3:49 am

Regenerative medicine contributed to patient care in 2020 more than ever before, bolstered by synergies in research, practice and education. Mayo Clinics Center for Regenerative Medicine is at the forefront of a biotherapy revolution in which health care advances from treating disease to restoring health.

The centrality of the body to regenerate itself is paving the way for new horizons in regenerative care. The triad of protecting against disease, preventing disease progression and promoting healing is at the core of the regenerative vision, says Andre Terzic, M.D., Ph.D., director of Mayo Clinics Center for Regenerative Medicine. To this end, the regenerative toolkit has grown more robust over the past year with new technologies now available to boost the bodys ability to repair and restore health of an organ and importantly of the patient as a whole.

The convergence of research, practice and education, empowered by strong innovation and advanced biomanufacturing, is creating an increased level of readiness for applying validated regenerative science to new areas of health care, Dr. Terzic says.

Practice advancement

A deeper understanding of the biology of health and disease is driving the ongoing regenerative medicine evolution.

The remarkable progress in science that is advancing our fundamental comprehension of both health and disease has guided the informed and responsible development of patient-ready curative strategies, says Dr. Terzic.

New discoveries at Mayo Clinic that may shape future practice include:

Validating safety and efficacy of

stem cell therapy for heart failure. The largest regenerative medicine clinical trial to date for heart failure, spanning 39 medical centers and 315 patients from 10 countries, validated the long-term safety of stem cell therapy. The late-stage research found stem cell therapy shows particular benefit for patients with advanced left ventricular enlargement. This Mayo Clinic-led study offers guidance on which patients are most likely

to respond to stem cell therapy for heart failure.

Uncovering stem cell activation of healing. Mayo Clinic researchers uncovered stem cell-activated molecular mechanisms of healing after a heart attack. Stem cells restored the makeup of failing cardiac muscle back to its condition before the heart attack, providing an intimate blueprint of how they may work to heal diseased tissue. This research offers utility to delineate and interpret complex regenerative outcomes.

Discovering a molecular light switch. Mayo Clinic research discovered a molecular switch that turns on a substance that repairs neurological damage. This early research could bolster a therapy approved by the Food and Drug Administration, and that could lead to new strategies for treating diseases of the central nervous system such as multiple sclerosis.

The federal regulatory environment is making it possible to more seamlessly integrate new discoveries into the practice. The 21st Century Cures Act, for example, seeks to create an accelerated path to market for safe, validated procedures that could provide new therapies for patients with serious conditions.

To read the rest of this article on the Center for Regenerative Medicine blog, visit http://www.regenerativemedicineblog.mayoclinic.org.

Read more from the original source:
Regenerative medicine is advancing health care in diverse ways - Hometown Focus

Posted in Stem Cell Research | Comments Off on Regenerative medicine is advancing health care in diverse ways – Hometown Focus

Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism…

Posted: January 23, 2021 at 3:49 am

New York, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Increased investment in advanced technologies for treatment of genetic and chronic diseases is driving growth of the regenerative medicine market.Market Size USD 7.34 Billion in 2019, Market Growth - CAGR of 15.6%, Market TrendsApplications in COVID-19 vaccine.

The global regenerative medicine market is forecast to reach a market size of USD 23.57 Billion by 2027, and register a robustly incline revenue growth, according to a new report by Reports and Data. Primary factors driving demand for regenerative medicines are advancements in surgical technology and monitoring devices, and major increase in prevalence of complex and degenerative diseases. Upsurge in incidence of cancers has been resulting in increasing research into stem cell therapy. Growth in research and development activities in emerging countries and rising focus on stem cell research is resulting in significant growth in the global revenue of regenerative medicine market.

Stem cell technology is growing rapidly and continues to play a crucial role in regenerative medicine and the related field. This technology opens up the possibility of treating Parkinsons Disease, arthritis, and spinal cord injury. Increase in demand for stem cell technology is a major factor driving growth of the regenerative medicine market.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3735

Recent developments in regenerative medicine for 3D bioprinting, stem cell treatment for heart repair, and vision loss has created demand for additional investments in the R&D of the technology to help with other diseases.

The COVID-19 impact:

Demand for regenerative medicine has witnessed increased demand during the COVID-19 pandemic. Regenerative medicine helps in understanding a mechanism of infection and to develop ways to prevent the spread of the virus. It is also being used to create advanced treatments to treat persons infected by the COVID-19 virus. Private companies are also using it to develop an effective vaccine for COVID-19.

Regenerative Medicine Market Size, Share & Industry Demand By Product (Tissue-Engineered Products, Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies), By Application (Musculoskeletal Disorders, Oncology, Wound Care, By Material), and Region, Segment Forecast to 2027, To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/regenerative-medicine-market

Further key findings from the report suggest

List of Key Companies Identified in the Regenerative Medicine Market Report:

Order Now: https://www.reportsanddata.com/checkout-form/3735

For the purpose of this report, Reports and Data has segmented into the global regenerative medicine market on the basis of product, application, material, and region:

Browse similar research reports:Cell Therapy Market By Therapy Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), By Therapeutic Area (Malignancies, Autoimmune Disorders, Musculoskeletal Disorders), By Cell Type, And By End User, Forecasts To 2027

Tissue Engineering Market Size, Growth & Analysis, By Material, By Application (Cancer, Urology, Neurology, Dental, Cell Banking & Cord Blood, Gynecology, Integumentary/Skin, Spine, Musculoskeletal, & Orthopedics, Vascular & Cardiology), And Region, Segment Forecasts To 2027

Gene Expression Market By Product And Services (Equipment, Consumables, And Services), By Capacity (Low- To Mid- Plex Gene Expression Analysis And High-Plex Gene Expression Analysis), By Application (Diagnostic, Drug Discovery, Research), And Segment Forecasts To 2027

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

Head of Business Development

Reports And Data | Web: http://www.reportsanddata.com

Direct Line: +1-800-819-3052

E-mail: sales@reportsanddata.com

Read full Press Release at:https://www.reportsanddata.com/press-release/global-regenerative-medicine-market

Excerpt from:
Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism...

Posted in Stem Cell Research | Comments Off on Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism…

Assistant Professor in Stem Cell Biology or Regenerative Biology job with University of California, Irvine | 312638 – The Chronicle of Higher…

Posted: January 23, 2021 at 3:49 am

Assistant Professor in Stem Cell Biology or RegenerativeBiology

Applications are invited for a tenure-track faculty position at thelevel of Assistant Professor in the Department of Developmental andCell Biology. We seek candidates with an interest in stem cell orregeneration biology, broadly defined. Applicants should pursueresearch in the major areas of interest of the department,including, but not limited to developmental biology, stem celland/or niche biology, regeneration and cancer stem cells. Prioritywill be given to candidates whose research will benefit frominterdisciplinary collaborations, interactions with members of thedepartment (http://devcell.bio.uci.edu), andfrom affiliation with campus centers and institutes.

The successful applicant is expected to conduct a vibrant researchprogram, contribute to the teaching and service missions of theUniversity of California, and share our commitment to diversity,equity and inclusion. Please send a curriculum vitae, 3-pagesummary of research accomplishments and goals, 1-page statement ofteaching and mentoring experience and philosophy, 1-page statementhighlighting past and/or potential contributions to diversity,equity and inclusion, and at least three letters of reference viathe online recruitment URL: https://recruit.ap.uci.edu/apply/JPF06561. Evaluation criteria for the research, teaching, and diversitystatements are provided at the online recruitment URL. Applicationscompleted by March 7, 2021 will be granted full consideration. Anyquestions about the suitability of an applicant for thisopportunity can be directed to the search chair, Peter Donovanpdonovan@uci.edu.

The UCI School of Biological Sciences is recognized as a nationalleader in the development of programs designed to increase theparticipation of underrepresented groups in the biomedical sciencesand is firmly committed to the ideals of equity, diversity, andinclusion (https://port.bio.uci.edu/about/,https://equity.bio.uci.edu). UCIis an Hispanic-Serving Institution, an Asian American and NativeAmerican Pacific Islander Serving Institution, and a chartermember of the AAAS SEA Change initiative that supportsinstitutional efforts to increase access and success for students,faculty and staff from groups marginalized in STEMM (https://www.aaas.org/news/four-new-charter-members-join-sea-change).Programs are available to meet the needs of dual-career academicpartners. Faculty are eligible for subsidized housing and aMortgage Origination Program. UC Irvine (https://uci.edu) is located 10 minutes fromthe coast (https://www.youtube.com/watch?v=82ARz3B60pU),is consistently ranked among the nations top 10 publicuniversities, and has recently been designated the #1 universitydoing the most for the American dream. The city of Irvine is hometo excellent parks, schools, entertainment opportunities, and adiverse citizenry.

The University of California, Irvine is an EqualOpportunity/Affirmative Action Employer advancing inclusiveexcellence. All qualified applicants will receive consideration foremployment without regard to race, color, religion, sex, sexualorientation, gender identity, national origin, disability, age,protected veteran status, or other protectedcategories covered by the UC nondiscrimination policy. A recipientof an NSF ADVANCE award for gender equity, UCI is responsive to theneeds of dual career couples, supports work-life balance through anarray of family-friendly policies, and is dedicated to broadeningparticipation in higher education.

The University of California is committed to creating andmaintaining a community dedicated to the advancement, application,and transmission of knowledge and creative endeavors throughacademic excellence, where all individuals who participate inUniversity programs and activities can work and learn together in asafe and secure environment, free of violence, harassment,discrimination, exploitation, or intimidation. With thiscommitment, as well as a commitment to addressing all forms ofacademic misconduct, UC Irvine conducts institutional referencechecks for candidate finalists to whom the department or otherhiring unit would like to extend a formal offer of appointment intoLadder Rank Professor or Professor of Teaching series, at all ranks(i.e., assistant, associate, and full). The institutional referencechecks involve contacting the administration of the applicantsprevious institution(s) to ask whether there have beensubstantiated findings of misconduct that would violate theUniversitys Faculty Code of Conduct. To implement this process, UCIrvine requires all candidates of Ladder Rank Professor orProfessor of Teaching series, at all ranks (i.e., assistant,associate, and full) to complete, sign, and upload the formentitled Authorization to Release Information into AP RECRUIT aspart of their application. If the candidate does not include thesigned authorization to release information with the applicationmaterials, the application will be considered incomplete. As withany incomplete application, the application will not receivefurther consideration. Although all applicants for facultyrecruitments must complete the entire application, only finalists(i.e., those to whom the department or other hiring unit would liketo extend a formal offer) considered for Ladder Rank Professor orProfessor of Teaching series, at all ranks (i.e., assistant,associate, and full) positions will be subject to institutionalreference checks.

REQUIREMENTS Curriculum Vitae Cover Letter Three letters of Reference Statement of Research Three pages.1. One page describing the significance and impact of your graduateand postdoctoral research.2. Two pages providing a plan for your future independent researchprogram that indicates how your research program will synergizewith the research environment at UCI (see e.g., https://www.bio.uci.edu/centers-institutes) Statement of Teaching One page.1. Describe any experience teaching/lecturing toundergraduates/graduate students or other populations and mentoringothers.2. Explain your teaching philosophy and describe how you willengage in teaching strategies that are effective in diversepopulations. Statement of Contributions to Diversity(http://www.uci.edu/diversity) One page.1. Indicate how you have demonstrated awareness of the issues facedby historically underrepresented or economically disadvantagedgroups and the benefits of a diverse and inclusive faculty.2. Provide evidence (if any) of your track record and success inactivities aimed at reducing barriers in education or research forunderrepresented or disadvantaged groups.3. Detail your specific plans (if any) to contribute through campusprograms, new activities, or through national or off-campusorganizations.

Read the original here:
Assistant Professor in Stem Cell Biology or Regenerative Biology job with University of California, Irvine | 312638 - The Chronicle of Higher...

Posted in Stem Cell Research | Comments Off on Assistant Professor in Stem Cell Biology or Regenerative Biology job with University of California, Irvine | 312638 – The Chronicle of Higher…

Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada – BioSpace

Posted: January 23, 2021 at 3:49 am

Calgary, Alberta--(Newsfile Corp. - January 22, 2021) - .Hemostemix Inc (TSXV: HEM) (OTC: HMTXD) ("Hemostemix" or the "Company") is pleased to announce it has signed the Building Relationships Entrepreneurs & Dealmakers (BREAD) contract with the Department of Foreign Affairs, Trade and Development. An initiative to assist high-potential, biotech focused Canadian Small and Medium Enterprise (SMEs), the program is designed to accelerate the growth of Hemostemix and other Canadian biotechnology companies.

"We are actively working with the Trade Commissioner Service of CANADA in the USA, Japan and South Korea to source qualified partners to go to market with," stated Thomas Smeenk, CEO. "The BREAD agreement marks our Company's starting point to out-license ACP-01, and it generates our sponsorship into BioCom."

ABOUT THE TRADE COMMISSIONER SERVICE OF CANADA

The Trade Commissioner Service (TCS) plays an active role in helping Canadian companies achieve their goals of growth into international markets. Its services focus on helping companies prepare for international markets, assessing market potential, finding qualified contacts and partners and resolving problems.

ABOUT HEMOSTEMIX

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up", which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visitwww.hemostemix.com.

For further information, please contact:

Thomas Smeenk, President, CEO & Co-FounderSuite 1150, 707 - 7thAvenue S.W., Calgary, Alberta T2P 3H6Phone: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its common shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials studies and analysis, including the midpoint analysis, being equivalent to or better than previous research, trials or studies as well as management's expectations of anticipated results; Hemostemix's general and administrative costs remaining constant; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and the Litigation. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory futility analysis and the results of such and future clinical trials; litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website atwww.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visithttps://www.newsfilecorp.com/release/72606

Read more from the original source:
Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada - BioSpace

Posted in Stem Cell Research | Comments Off on Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada – BioSpace

Promising Steps Toward Retinal Cell Transplants to Fight Blindness – HealthDay News

Posted: January 23, 2021 at 3:49 am

TUESDAY, Jan. 19, 2021 (HealthDay News) -- A promising step toward using retinal cell transplants to treat blindness is reported in a new study.

Adult retinal stem cells from deceased human donors survived when they were transplanted into the eyes of non-human primates, according to the researchers.

The cells were taken from the retinal pigment epithelium (RPE). It is a layer of cells that supports and nourishes the retina, the light-sensitive tissue that lines the back of the eye. It helps maintain normal vision.

RPE dysfunction can result in disorders such as macular degeneration and can cause blindness, which affects about 200 million people worldwide.

"The results of this study suggest human adult donor RPE is safe to transplant, strengthening the argument for human clinical trials for treating retina disease," said co-lead investigator Timothy Blenkinsop. He's an assistant professor of cell, developmental and regenerative biology at the Icahn School of Medicine at Mount Sinai, in New York City.

For the study, his team transplanted cell-derived patches under the primates' maculas. The transplants remained stable and integrated for at least three months with no serious side effects, such as being attacked by the immune system or light sensitivity, according to the report published Jan. 14 in the journal Stem Cell Reports.

The stem cell-derived RPE assumed some of the function of the original RPE, and also supported a photoreceptor that helps with functions such as light and water absorption, the findings showed.

"We have demonstrated human cadaver donor-derived RPE at least partially replaces function in the macula of a non-human primate," Blenkinsop said in a Mount Sinai news release.

Results of animal studies, however, often differ in humans.

The study authors said RPE stem cell transplantation is a possible treatment for macular degeneration, but further research is needed to confirm that.

Future studies should assess whether such transplants can restore vision in people and diseased eyes in non-human primates, the researchers said.

More information

The U.S. National Eye Institute has more on age-related macular degeneration.

SOURCE: Mount Sinai Hospital, news release, Jan. 14, 2021

Link:
Promising Steps Toward Retinal Cell Transplants to Fight Blindness - HealthDay News

Posted in Stem Cell Research | Comments Off on Promising Steps Toward Retinal Cell Transplants to Fight Blindness – HealthDay News

Gene Pathway Linked to Development of Schizophrenia – Psychiatric Times

Posted: January 23, 2021 at 3:49 am

In an award-winning study, researchers from The University of Texas Health Science Center at Houston (UTHealth) discovered a gene signaling pathway linked to a higher risk for developing schizophrenia by observing human-induced pluripotent stem cells created from blood samples of a single family. The pathway, phosphoinositide 3-kinase/glycogen synthase kinase 3 (PI3K/GSK3), contains differentially expressed genes, including serum-glucocorticoid kinase 1 (SGK1). This is an inhibitor of GSK3 beta and has been associated with schizophrenia.1

We believe this has direct implications for the treatment of patients, senior author Consuelo Walss-Bass, PhD, MD, said to the press. There is a new antipsychotic that just received approval from the Food and Drug Administration that directly targets the pathway we identified as dysregulated in neurons from the patients, and several other antipsychotics also target this pathway. This could help pinpoint who may respond better to treatments.2

Walss-Bass, the first author, and postdoctoral research fellow Laura Stertz, PhD, took blood samples from members of a large Costa Rican family with multiple individuals with schizophrenia. The blood cells were changed into stem cells using human-induced pluripotent stem cell (hiPSC) technology. These cells were then redirected to become brain neurons. This allowed them to be studied in a virtual biopsy and compared to neurons from family members who did not have schizophrenia.

In the biopsies, researchers saw 5 schizophrenia candidate genes previously identified by genome association studies. Alterations caused by gene SGK1, which inhibits GSK3 activity, are linked to whether a person has a higher risk of schizophrenia.

Walss-Bass had this to say on the discovery: Mental health research has lagged behind because we don't know what is happening biologically. We are diagnosing people based on what they are telling us. Even postmortem, the brain tissue in mental health disorders looks perfectly fine. In Alzheimer disease, you can see a difference compared to controls. But not in psychiatric disorders. Now by studying virtual brain biopsies, we can tell what is happening biologically.2

Walss-Bass also said that identifying patients with specific biological pathway markers could identify them as the best candidates for medications. This pre-emptive, personal pharmacology may be what is needed to best treat psychiatric disorders.

We were able to find significant, meaningful differences with a small control group, Walss-Bass said. Neurons of patients with schizophrenia had alterations in the signaling pathway. This research may help to understand how or why some antipsychotics targeting GSK3 work and also to develop other target-specific medications.2

References

1. Stertz L, Di Re J, Pei G, Fries G, et al. Convergent genomic and pharmacological evidence of PI3K/GSK3 signaling alterations in neurons from schizophrenia patients. Neuropsychopharmacol. 2020;46:673682.

2. University of Texas Health Science Center at Houston. Gene pathway linked to schizophrenia identified through stem cell engineering. News release. Science Daily. December 21, 2020. https://www.sciencedaily.com/releases/2020/12/201221134136.htm

Here is the original post:
Gene Pathway Linked to Development of Schizophrenia - Psychiatric Times

Posted in Stem Cell Research | Comments Off on Gene Pathway Linked to Development of Schizophrenia – Psychiatric Times

Weekly line: What the new coronavirus variants mean for vaccines, transmission, and more – The Daily Briefing

Posted: January 20, 2021 at 6:52 pm

News and research regarding emerging new coronavirus variants are moving fast. To help you keep up, here's a 101-level explainer on what the new variants are, where they emerged, and more.

This explainer covers:

By now, we all know that officials reported the first cases of the novel coronavirus, known as SARS-CoV-2, late last year in Wuhan, China. The virus quickly spread throughout the world, touching every continent and nearly every country.

Throughout the pandemic, researchers have been testing samples of SARS-CoV-2 to detect whether the novel coronavirus developed any mutations as it spread, which can occur with RNA viruses such as influenza, HIV, the new coronavirus, and more. By May, scientists had identified at least one mutation, known as D614G, but research on whether the mutation made the virus more transmissible was largely inconclusive. However, by September, researchers had catalogued "more than 12,000 mutations in SARS-CoV-2 genomes," Nature's Ewen Callaway reports.

According to Callaway, many scientists suspected that, if a mutation didn't help the novel coronavirus to spread easier, it likely emerged when the virus was first mutating to jump from animals to humans or from human to human. But scientists didn't think it was likely that the virus would mutate to become more transmissible among humans at this point, because "[a]t a time when nearly everyone on the planet is susceptible, there is likely to be little evolutionary pressure on the virus to spread better, so even potentially beneficial mutations might not flourish," Callaway writes.

Put another way, William Hanage, an epidemiologist at the Harvard T. H. Chan School of Public Health, told Callaway, "As far as the virus is concerned, every single person that it comes to is a good piece of meat. There's no selection to be doing it any better."

Fast-forward just a few months, however, and officials in the United Kingdom had some troubling news. On Dec. 8, 2020, British officials announced that scientists had discovered a new, potentially far-more-contagious variant of the novel coronavirus in the United Kingdom. U.K. Prime Minister Boris Johnson and England's CMO Chris Whitty said scientists identified the new variantlabeled B 1.1.7through Public Health England's genomic surveillance. U.K. officials said the variant had about 20 mutations, including several that affect how the virus attaches to and infects cells in the body. Specifically, one of the mutations on B 1.1.7, called N501Y, improves how the spike protein of the viruswhich is the part of the virus that infects human cellsattaches to the ACE2 receptor on human cells, meaning the virus is more likely to infect cells successfully.

Johnson at the time said scientists believed the new variant was more infectious than the original version of the novel coronavirus, and the variant quickly became the dominant type of SARS-CoV-2 spreading throughout the country. According to recent research, B.1.1.7 appears to be about 56% more contagious than the unmutated virus, and researchers have now detected the variant in at least 45 countries, including the United States.

In the United States, researchers so far have detected B.1.1.7 in a handful of states, but experts say its possible the new variant is more widespread than we know. That's because the United States currently lacks a nationwide system for tracking how coronavirus genomes mutate, with researchers doing genome sequencing on fewer than 3,000 samples a week. Many of the Americans infected with B.1.1.7 haven't traveled recently, which suggests that the variant is already circulating throughout the country via community spread, officials have said.

But B.1.1.7 isn't the only new coronavirus variant on scientists' radar. They've also discovered a new variant in South Africa, called B.1.351, that similarly features the N501Y mutation, as well as an additional mutation called E484K. The E484K mutation occurs on a part of the spike protein that's instrumental in attaching the virus to ACE2 receptors, and it's also been found in a coronavirus variant circulating in Brazil.

Additionally, on Wednesday, researchers in Ohio reported identifying two additional new variants, including one that appears to be more transmissible than the original version of SARS-CoV-2 and may have originated in the United States. Not much is known about those new variants at this time, but researchers said the variant that may be more transmissible has become the dominant variant circulating in Columbus, Ohio.

Experts also predict that we could see additional more-contagious new variants of the novel coronavirus as more people gain immunity to the pathogen. Salim Abdool Karim, chair of South Africa's Covid-19 ministerial advisory committee, told the Financial Times, "We're going to see this occur more commonly now than in 2020, as we vaccinate and as more people are infected," because the virus will evolve to help it continue to spread.

FDA has warned health care providers that the new variants might elude some tests for the novel coronavirus and trigger false-negative results. FDA said that likelihood is low, but it noted three tests Applied DNA Sciences' Linea test, Mesa Biotech's hand-held Accula test, and Thermo Fisher's TaqPath combo kitthat might produce inaccurate results because of the variants' mutations. In a statement, FDA Commissioner Stephan Hahn said the agency is "working with authorized test developers and reviewing incoming data to ensure that health care providers and clinical staff can quickly and accurately diagnose patients infected with SARS-CoV-2, including those with emerging genetic variants."

But there is some good news: So far, there's no evidence that the new coronavirus variants cause more severe illness or higher mortality than the original version of the virus.

And although experts have expressed concern that some variants may be more resistant to current treatments for Covid-19, they say there's no evidence indicating as much so far, at least for the currently known variants.

For instance, Gilead Sciences is testing its Covid-19 treatment remdesivir on both B.1.1.7 and B.1.351, but the company's CEO, Daniel O'Day, on Monday said he believes remdesivir will be effective against them. "Remdesivir works at the source in the cell where the virus replicates, and what we know is, in these new variants, that part of the cell is not changing at all," he said.

It's more uncertain, however, whether monoclonal antibody treatments for Covid-19 will be effective against variants that have mutations to the portion of the novel coronavirus's spike protein that's targeted by those treatments. As a result, Eli Lilly CEO Dave Ricks on Tuesday told CNBC that he expects the company's antibody drug will be effective against B.1.1.7, but he's not sure whether it will work against B.1.351.

That's because B.1.351 "has more dramatic mutations to that spike protein, which is the target. Theoretically, it could evade our medicines," Ricks said. He added that Lilly intends to work with FDA to test different versions of the company's antibody drug against the new variants to gauge their effectiveness.

Separately, George Yancopoulos, Regeneron's research and development chief, on Monday said the company's antibody cocktail drug for Covid-19 could be effective against new coronavirus variants. "We think having a cocktail makes it more likely you'll be able to deal" with the new variants, because "[i]t reduces the likelihood that a single variant can become resistant to both antibodies in the cocktail," he said.

When it comes to vaccines, a study conducted by Pfizer and scientists from the University of Texas Medical Branch suggests that Pfizer's and BioNTech's coronavirus vaccine is effective in neutralizing the novel coronavirus with the N501Y mutation. That study hasn't yet been peer-reviewed, and it didn't look at the E484K mutation. Pfizer has said it plans to test its vaccine against the E484K mutation in coming weeks.

According to Medical News Today's Maria Cohut and Yella Hewings-Martin, experts have said Moderna's Covid-19 vaccine should be similarly effective against new variants.

Some studies have shown that viruses with the E484K mutation are not recognized as well by antibodies as other forms, meaning coronavirus variants with the E484K mutationsuch as B.1.351could potentially bypass immune protection. According to a pre-print paper from researchers at the Fred Hutchinson Cancer Research Center, the location of the E484K mutation is "the site of most concern for viral mutations." Overall, the paperwhich tracked how the antibodies in people who had recovered from Covid-19 fared against different variantsfound that while there was variability among the samples, some people experienced as much as a 10-fold drop in neutralization against variants with E484K.

Overall, however, while experts are concerned about the recent mutations, they say it's not likely that they'll render current Covid-19 vaccines and treatments entirely ineffective. According to experts, it would take yearsrather than monthsfor the novel coronavirus to mutate to a point where people's antibodies against the virus or currently authorized vaccines would become ineffective.

And as CDC recently explained, the United States' currently authorized Covid-19 vaccines "produce a 'polyclonal' response that targets several parts of the spike protein. The virus would likely need to accumulate multiple mutations in the spike protein to evade immunity induced by vaccines or by natural infection."

Jesse Bloom, an evolutionary biologist at the Fred Hutchinson Cancer Research Center, told the New York Times' Apoorva Mandavilli, "No one should worry that there is going to be a single catastrophic mutation that suddenly renders all immunity and antibodies useless." Noting that even the influenza virus needs between five and seven years to gather all the mutations necessary to evade immune recognition entirely, Bloom continued, "It is going to be a process that occurs over the time scale of multiple years and requires the accumulation of multiple viral mutations. It's not going to be like an on-off switch."

Regardless, vaccine manufacturers say they'll be monitoring whether they need to tweak their vaccines to address the new variants. For instance, BioNTech CEO Ugur Sahin recently said that, if the company's vaccine starts to lose its efficacy because of new variants, his company would be able to adjust its vaccine accordinglyand in an even shorter timeframe. "[T]he beauty of the messenger mRNA technology [that the BioNTech/Pfizer vaccine uses as a platform] is we can directly start to engineer a vaccine that completely mimics this new mutation and we could manufacture a new vaccine within six weeks," he said.

Since the United States doesn't yet possess the robust surveillance program needed to determine how widespread new coronavirus variants actually are in America, public health experts say the country essentially is "flying blind" when it comes to addressing them, the Times' Matt Apuzzo, Selam Gebrekidan, and Mandavilli report. Experts say implementing a national surveillance system in the United States would allow public health officials to warn people in areas affected by the new variants and quickly implement measures meant to stem their spread.

Without taking action to stop the new variants, and particularly B.1.1.7, they could become the dominant variants circulating in the United States within the next few weeks to a couple months, public health experts say. And while it's currently too soon to tell how the variants will affect the United States' coronavirus epidemic, experts are concerned more-contagious variants could accelerate the country's new case rate.

That's especially concerning because the United States already is seeing persistently high levels of hospitalizations and deaths tied to the novel coronavirus. Hospitals in some areas of the United States already are overwhelmed by a recent influx of Covid-19 patients, with some having to ration care. If the country sees new cases of the coronavirus and related hospitalizations accelerate even more, the situation could become increasingly diresimilar to what's happened in the United Kingdom, experts fear.

"Epidemiological models and Britain's experience indicate that, while only a few cases of the variant have been identified in the United States, it will likely become our dominant strain within a few months," Ashish Jha, a general internist and professor of global health at the Harvard T.H. Chan School of Public Health, and Robert Wachter, chair of the department of medicine at the University of California-San Francisco, write in a Washington Post opinion piece. And "a more infectious virus means more cases, which means more hospitalizations and deaths," they add.

As such, in addition to ramping up surveillance of the new variants in the United States, health officials say Americans need to double down on evidence-backed public health measures that curb the novel coronavirus's spread, such as wearing face masks, social distancing, and frequent hand washing.

"We don't have any evidence that the new variant can fundamentally evade masks, social distancing, or the other interventions," Jeff Barrett, director of the Covid-19 genomics initiative at the Wellcome Sanger Institute in the United Kingdom, told BBC News' Helen Briggs. "[W]e just need to apply them more strictly."

Further, health officials say federal and state health officials must work to get as many Americans vaccinated against Covid-19 as quickly as possible.

"We are in a race against time," Jennifer Nuzzo, an epidemiologist with the Johns Hopkins Center for Health Security, told the Post's Joel Achenbach and Ben Guarino. "We need to increase our speed in which we act so that we don't allow this virus to spread further and allow [B.1.1.7] to become the dominant one in circulation. The clock is ticking."

See the rest here:
Weekly line: What the new coronavirus variants mean for vaccines, transmission, and more - The Daily Briefing

Posted in Ohio Stem Cells | Comments Off on Weekly line: What the new coronavirus variants mean for vaccines, transmission, and more – The Daily Briefing

Stem cells on the ballot – Science Magazine

Posted: January 20, 2021 at 6:51 pm

California's ballot measures often reveal much about the broader U.S. policy environment. This is particularly true of the approval by the state's voters in November of Proposition 14, The California Stem Cell Research, Treatments, and Cures Initiative of 2020. Proposition 14 extends the 2004 ballot Proposition 71, which established the California Institute for Regenerative Medicine (CIRM) and authorized $3 billion in state-issued bonds for CIRM to fund stem cell and regenerative research and medicine (restricted to California). Proposition 14, which authorizes $5.5 billion over the next 10 years to continue CIRM's work, succeeded in part by informing voters of CIRM's successes and that its conflict-of-interest provisions are extremely strong. This state-level action is critical because, contrary to opponents' opinions, the overall policy environment for human stem cell research in the United States is in some ways worse now than when Proposition 71 passed.

Since 2004, CIRM has funded groundbreaking work on immune disorders, cancer, spinal cord injury, diabetes, and more. The result has been more than 90 stem cellrelated clinical trials (directly or indirectly supported by CIRM), almost 3000 scientific papers, and contributions to two cancer therapies approved by the U.S. Food and Drug Administration. The lives of many patients have improved because of CIRM. Notably, many CIRM-funded clinical trials rely on human embryonic or fetal stem cells, whereas the federal government currently does not fund any clinical trials using these types of cells.

Proposition 71 was motivated largely in response to restrictions on human embryonic stem cell research in the United States in 2004. However, although research was limited to a small number of human embryonic stem cell lines, there was no formal ban on federal funding of research on such stem cells. In addition, in 2004 there were no restrictions on federal funding of human fetal stem cell and tissue research; however, there is now near-complete blockage of federal funding for such research. And federal funding for human embryonic stem cell research is again at risk. On 4 September 2020, 22 Republican senators and 72 Republican House members wrote to President Trump requesting an end to all federal funding of human embryonic stem cell research. Could President Trump impose a ban that would be difficult to revoke? Or, could Republican senators manufacture a ban by legislative maneuvering on a budget reconciliation vote, which requires 60% support? Such maneuvering created the effectively permanent 1995 Dickey-Wicker amendment, which prohibits federal funding of any research in which human embryos are created or destroyed. Dickey-Wicker has limited research on in vitro fertilization methods and stalled progress on understanding early human development. It has not solved the problem of the many, perhaps 1 million frozen embryos in the United States that will not be used for in vitro fertilization and will be destroyed without benefit if not used for research. Vital long-term research is greatly harmed by the U.S. policy environment, with the likely outcome that many young scientists will avoid research using human embryonic stem cells and human fetal tissue.

Restrictions on valuable, ethical research appear particularly fool-hardy during a deadly pandemic. Research on viruses such as HIV and SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) can benefit greatly from work using mice that utilize human fetal stem cells and tissues to generate a human-like immune system. These mice allow evaluation of a human immune system in the contexts of infection mechanisms, generation of immunity, and drug response. These studies can be supported with Proposition 14 funds in California, but not with federal funds. It is crucial for the incoming Biden administration to evaluate the need for federal funding in these important areas with high-quality scientific input and evidence.

California's vote on Proposition 14 should also help the rest of the country appreciate the need to increase investments in biomedical research at the U.S. National Institutes of Health and other federal agencies. Current biomedical research expenditures amount to only a tiny fraction of the costs of disease, so an objective evaluation of appropriately increased research funding relative to disease costs is warranted. Once again, California is showing the way.

See the rest here:
Stem cells on the ballot - Science Magazine

Posted in California Stem Cells | Comments Off on Stem cells on the ballot – Science Magazine

Page 779«..1020..778779780781..790800..»